Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay5394 in Mild to Moderate Atopic Dermatitis
NCT07877155Phase 2Not yet recruiting
- Sponsor
- Tianjin Hemay Biotech
- Start
- Nov 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hemay5394 in atopic dermatitis (AD) (2 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Proportion of participants achieving Eczema Area and Severity Index 75% reduction at 4 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Hemay5394
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07877155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877155.